Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II – III invasive breast cancer: the OOTR-N001 study

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Chow LW, Ting AC, Cheung KL, Current status of breast cancer in Hong Kong. Chin Med J (Engl) 1997;110:474-8
   PubMed Web of Science ®Google Scholar
• Youlden DR, Cramb SM, Dunn NA, The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012;36:237-48
   PubMed Web of Science ®Google Scholar
• Iwata H, Sato N, Masuda N, Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol 2011;41:867-75
   PubMed Web of Science ®Google Scholar
• Taguchi T, Masuda N, Nakayama T, Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: kinki Breast Cancer Study Group (KBCSG)]. Oncology 2010;78:302-8
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Newman LA, Smith TL, Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9
   PubMed Web of Science ®Google Scholar
• Rastogi P, Anderson SJ, Bear HD, Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85
   PubMed Web of Science ®Google Scholar
• Bear HD, Anderson S, Smith RE, Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-27
   PubMed Web of Science ®Google Scholar
• Jacquin JP, Jones S, Magné N, Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. Breast Cancer Res Treat 2012;134:903-13
   PubMed Web of Science ®Google Scholar
• Bocca C, Bozzo F, Bassignana A, Miglietta A. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 2011;350:59-70
   PubMed Web of Science ®Google Scholar
• Chen C, Shen HL, Yang J, Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J Cancer Res Clin Oncol 2011;137:9-17
   PubMed Web of Science ®Google Scholar
• Ashok V, Dash C, Rohan TE, Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 2011;20:66-70
   PubMed Web of Science ®Google Scholar
• Young SD, Lafrenie RM, Clemons MJ. Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. Curr Oncol 2012;19:e75-83
   PubMed Web of Science ®Google Scholar
• Fabi A, Metro G, Papaldo P, Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol 2008;62:717-25
   PubMed Web of Science ®Google Scholar
• Chow LWC, Toi M. Prospective pilot study of the preoperative use of celecoxib (Celebrex™) and FEC for the treatment of locally advanced breast cancer. Breast Cancer Res Treat 2002;76:S54
   Web of Science ®Google Scholar
• Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 2003;278:37637-47
   PubMed Web of Science ®Google Scholar
• Olsen SR. Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice. Biomed Pharmacother 2005;59:S306-10
   PubMed Web of Science ®Google Scholar
• FDA statement on the halting of a clinical trial of the cox-2 inhibitor Celebrex. US Food and Drug Administration. 2004. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108384.htm [Last accessed 2 May 2012]
   Google Scholar
• Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. NIH news. US Department of Health and Human Services. Available from: www.nih.gov/news/pr/dec2004/od-20.htm [Last accessed 2 May 2012]
   Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80
   PubMed Web of Science ®Google Scholar
• Caldwell B, Aldington S, Weatherall M, Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006;99:132-40
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14
   PubMed Web of Science ®Google Scholar
• Kuroi K, Toi M, Tsuda H, Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 2006;13:38-48
   PubMedGoogle Scholar
• Common Terminology Criteria for Adverse Events v3.0 (CTACE). National Cancer Institute. Available from: ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf [Last accessed 3 May 2012]
   Google Scholar
• Schlesselman JJ, Reis IM. Phase II clinical trials in oncology: strengths and limitations of two-stage designs. Cancer Invest 2006;24:404-12
   PubMed Web of Science ®Google Scholar
• Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer–recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 2004;11:139-47
   PubMedGoogle Scholar
• Bear HD, Anderson S, Brown A, The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-74
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Raab G, Caputo A, Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-85
   PubMed Web of Science ®Google Scholar
• Toi M, Nakamura S, Kuroi K, Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 2008;110:531-9
   PubMed Web of Science ®Google Scholar
• Glynn SA, Prueitt RL, Ridnour LA, COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer 2010;10:626
   Google Scholar
• Chuah BY, Putti T, Salto-Tellez M, Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy. Ann Oncol 2011;22:1748-54
   PubMed Web of Science ®Google Scholar
• Kong X, Moran MS, Zhang N, Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011;47:2084-90
   PubMed Web of Science ®Google Scholar
• Chow LWC, Yip AYS, Chan RHW, Toi M. Neoadjuvant use of 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by docetaxel (T) with concurrent COX-2 inhibitor in women with stage II/III breast cancer: a subanalysis of cardiac function. J Clin Oncol 2010;28:e11073
   Google Scholar